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Background: Breast cancer cells deﬁcient for BRCA1 are hypersensitive to agents inducing DNA double-strand
breaks (DSB), such as bifunctional alkylators and platinum agents. Earlier, we had developed a comparative genomic
hybridisation (CGH) classiﬁer based on BRCA1-mutated breast cancers. We hypothesised that this BRCA1-like
CGH
classiﬁer could also detect loss of function of BRCA1 due to other causes besides mutations and, consequently, might
predict sensitivity to DSB-inducing agents.
Patients and methods: We evaluated this classiﬁer in stage III breast cancer patients, who had been randomly
assigned between adjuvant high-dose platinum-based (HD-PB) chemotherapy, a DSB-inducing regimen, and
conventional anthracycline-based chemotherapy. Additionally, we assessed BRCA1 loss through mutation or
promoter methylation and immunohistochemical basal-like status in the triple-negative subgroup (TN subgroup).
Results: We observed greater beneﬁt from HD-PB chemotherapy versus conventional chemotherapy among
patients with BRCA1-like
CGH tumours [41/230 = 18%, multivariate hazard ratio (HR) = 0.12, 95% conﬁdence interval
(CI) 0.04–0.43] compared with patients with non-BRCA1-like
CGH tumours (189/230 = 82%, HR = 0.78, 95% CI 0.50–
1.20), with a signiﬁcant difference (test for interaction P = 0.006). Similar results were obtained for overall survival (P
interaction = 0.04) and when analyses were restricted to the TN subgroup. Sixty-three percent (20/32) of assessable
BRCA1-like
CGH tumours harboured either a BRCA1 mutation (n = 8) or BRCA1 methylation (n = 12).
Conclusion: BRCA1 loss as assessed by CGH analysis can identify patients with substantially improved outcome
after adjuvant DSB-inducing chemotherapy when compared with standard anthracycline-based chemotherapy in our
series.
Key words: array comparative genomic hybridisation, BRCA1, breast cancer, high-dose chemotherapy, platinum
salt, predictive marker
introduction
Most evidence for beneﬁt of adjuvant systemic treatment
comes from large clinical trials carried out in the general breast
cancer population [1]. However, these trials do not generally
consider the molecular heterogeneity of breast cancers,
which may be related to treatment beneﬁt of
individual patients. The disadvantage of these traditional
trials can be best illustrated with the example of trastuzumab.
Its efﬁcacy among breast cancer patients with an ampliﬁcation
of the human epidermal growth factor receptor-2 (HER2-
positive) would likely have been overlooked in analyses of the
general population since a large percentage of breast cancers is
HER2 negative and therefore does not beneﬁt from
trastuzumab. Several systemic treatments might therefore have
been discarded in the past, although they may have
been proven beneﬁcial if tested in a predeﬁned targeted
population.
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platinum salts, which are not commonly used, with the
exception of cyclophosphamide (Endoxan; Baxter
International, Deeﬁeld, IL, USA), due to their relatively high
toxicity and low level of efﬁcacy in unselected breast cancer
patients [2–5]. These agents act via formation of DNA cross
links resulting in DNA double-strand breaks (DSBs). Preclinical
and clinical evidence has emerged that a possible target of DSB-
inducing agents are tumours with a non-functional BRCA1
protein, such as tumours with BRCA1 mutations [6–9].
BRCA1-mutated tumours showed hypersensitivity to these
agents, which may be related to the role of BRCA1 in
homologous recombination, a conservative mechanism for
error-free repair of DSBs. Absence of homologous recom-
bination, such as in BRCA1-mutated tumours, prohibits error-
free repair of DSBs, which is reported to lead to cell death [10].
Furthermore, defects in homologous recombination activate
alternative more error-prone mechanisms such as non-
homologous end joining, presumably leading to genomic
instability [11–13]. BRCA1-loss-related instability can be
visualised by array comparative genomic hybridisation (aCGH)
showing characteristic copy number aberrations (CNAs) in
deﬁned genomic loci in a tumour [14–17].
We have previously developed an aCGH BRCA1-like classiﬁer
aimed to differentiate between BRCA1-mutated and sporadic
breast cancers with reasonable accuracy based on their
characteristic CNAs [17]. This test has been shown to have
a relatively high sensitivity but a somewhat lower speciﬁcity for
BRCA1-mutated tumours. We hypothesised that tumours testing
‘‘false positive’’ with the classiﬁer could represent tumours with
functional BRCA1 loss due to other causes than mutations, such as
BRCA1 promoter methylation. If true, the BRCA1-like
CGH
classiﬁer would identify a larger fraction of breast cancer patients,
who might beneﬁt from DSB-inducing agents.
The aim of this study was to determine whether the BRCA1-
like
CGH classiﬁer was capable of identifying patients beneﬁting
from DSB-inducing agents. For this purpose, we studied
a representative sample of stage III HER2-negative breast
cancer patients who had been randomly assigned between two
treatment arms; high-dose, platinum-based, alkylating
chemotherapy (HD-PB chemotherapy), which is a DSB-
inducing regimen, and a standard anthracycline-based regimen
(conventional chemotherapy) in a trial with long-term follow-
up [18]. We restricted our analyses to HER2-negative patients,
as in the pivotal study HER2-positive patients did not beneﬁt
from HD-PB chemotherapy [18]. Since patients in our study
had been randomised, we could differentiate between selective
HD-PB chemotherapy beneﬁt and general chemotherapy
beneﬁt. Accordingly, we evaluated whether the effect of HD-PB
chemotherapy on survival differed by BRCA1-like
CGH
classiﬁcation based on multivariate proportional hazards
regression with an interaction term. To explore the biology of
BRCA1-like
CGH classiﬁed tumours, we studied their association
with other markers for BRCA1 loss. We studied basal-like status
deﬁned by immunohistochemistry (IHC) since this had been
associated with BRCA1-mutated breast cancers [19, 20].
Secondly, we assessed BRCA1 promoter methylation, which has
been reported as an alternative mechanism for reduced BRCA1
expression in basal-like breast cancer [21, 22]. Lastly, BRCA1
mutation status was determined. Since we found a strong
association between the BRCA1-like
CGH classiﬁed tumours and
triple-negative status and these markers have all been associated
with triple negativity, we investigated them in the triple-
negative subgroup (TN subgroup).
patients and methods
BRCA1-like
CGH classiﬁcation
A BRCA1-like
CGH classiﬁer, which calculates the probability of belonging to
the BRCA1-mutated class, had previously been constructed (see
supplemental Appendix B, available at Annals of Oncology online). We
determined the optimal cut-off of the BRCA1-like
CGH probability score to
identify breast cancer patients likely to beneﬁt from DSB-inducing agents
(for details, see supplemental Appendix B, available at Annals of Oncology
online). For this purpose, we studied metastatic breast cancer (MBC)
patients who had participated in phase II studies of HD-PB chemotherapy
(n = 39, MBC series described in supplemental Appendix B, available at
Annals of Oncology online) [23–25]. We carried out BRCA1-like
CGH class
detection on each individual aCGH tumour proﬁle, resulting in either
a BRCA1-like
CGH or a non-BRCA1-like
CGH score.
patient selection
We studied stage III HER2-negative breast cancer patients from a large
randomised controlled trial (RCT) carried out in the Netherlands between
1993 and 1999 in the adjuvant setting (stage III series). Eligibility criteria
have been published previously [18] (see supplemental Appendix A,
available at Annals of Oncology online). Patients were randomly assigned
between conventional chemotherapy (5*FEC: 5-ﬂuorouracil 500 mg/m
2,
epirubicin 90 mg/m
2, cyclophosphamide 500 mg/m
2) and HD-PB
chemotherapy (4*FEC, followed by 1*CTC: cyclophosphamide 6000 mg/
m
2, thiotepa 480 mg/m
2 and carboplatin 1600 mg/m
2) [18].
Due to practical (ﬁnancial) constraints, we did not evaluate all 621
HER2-negative breast cancer patients, but randomly selected 320 HER2-
negative patients (320/621 HER2-negative cases, 51%). Patient samples
were included in analyses if formalin-ﬁxed parafﬁn-embedded (FFPE)
primary tumour tissue consisting of more than 60% of tumour cells was
available and if they had been treated per-protocol. Figure 1 summarises the
ﬂow of patients through the study. All trials described in this article were
approved by the Institutional Review Board of the Netherlands Cancer
Institute. This study was designed according to the REporting
recommendations for tumor MArker prognostic studies (REMARK)
guidelines [27] following the predictive marker trial design of ‘Indirect
assessment: Marker by treatment interaction design, test of interaction’ as
described by Sargent et al. [28].
comparative genomic hybridisation
Genomic DNA was extracted from FFPE primary tumours as previously
described [29]. For 11 patients, only lymph node tissue containing primary
tumour tissue, removed at ﬁrst diagnosis, was available. Of 11 samples,
DNA concentrations were too low for direct aCGH analysis and these
samples were ampliﬁed with the BioScore
  Screening and Ampliﬁcation Kit
(42440, Enzo Life Sciences BVBA, Zandhoven, Belgium). Tumour DNA
and reference DNA were labelled and hybridised as published previously
(see supplemental Appendix A, available at Annals of Oncology online) [30].
To determine the quality of each CGH proﬁle and to be able to compare
experiments, we used a proﬁle quality and hybridisation quality score (see
supplemental Appendix A, available at Annals of Oncology online).
mutation and methylation analyses
We screened for 38 known BRCA1 mutations using allelic discrimination
and multiplex PCR accounting for 853 of 1166 BRCA1 families (73%) in
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online) (M. K. Schmidt et al., unpublished data). Each putative mutation
identiﬁed was validated using capillary sequencing.
Hypermethylation of the BRCA1 promoter was assessed using a custom
methylation speciﬁc MLPA set according to the manufacturer’s protocol
(ME005-custom; MRC-Holland, Amsterdam, the Netherlands). Probe
sequences of the MLPA set are available on request (info@mlpa.com). DNA
fragments were analysed on a 3730 DNA Analyzer (Applied Biosystems, Foster
City, CA, USA). For normalisation and analysis, the Coffalyzer program was
used (MRC-Holland, Amsterdam, The Netherlands); peak heights below 250
were excluded from further analyses. When both BRCA1 probes showed
methylation (threshold of 0.2; MRC-Holland), we classiﬁed the result as
BRCA1 promoter methylation.
histopathology
Haematoxylin and eosin-stained slides were scored for tumour percentages.
Estrogen receptor (ER), progesterone receptor (PR), P53 and HER2 status
were determined by IHC as described previously [18, 32]. We used Pronase
pretreatment for the epidermal growth factor receptor (EGFR Ab-10 clone
111.6; 1 : 200; Neomarkers / Lab Vision Corporation, Fremont, CA, USA;
EGFR clone 31G7, 1 : 400; Zymed / Invitrogen, Carlsbad, CA, USA) and
the standard procedure for cytokeratin 5/6 staining (CK5/6, clone D5/16
B4, M7237, 1 : 200; Dako, Glostrup, Denmark). CK5/6 and EGFR were
considered positive if any staining of tumour cells was observed. Tumours
were classiﬁed as basal-like according to the Nielsen basal-like breast cancer
IHC deﬁnition [33].
statistical analysis
Differences between groups of interest were tested using Fisher’s exact tests.
Survival curves were generated using the Kaplan–Meier method and
compared using log-rank tests. Hazard ratios (HR) were calculated using
Cox proportional hazards regression.
Recurrence-free survival (RFS) was calculated from randomisation to
appearance of local or regional recurrence, metastases or to death from any
cause [18]. All other events were censored. Overall survival (OS) was time
from randomisation to death from any cause or end of follow-up. Median
RFS and OS were 7.6 and 8.2 years, respectively, for all 230 patients.
Patients alive at last follow-up were censored at that time. All treatment
comparisons were based on patients who completed their assigned
treatment (per-protocol analysis) to secure the correct correlation between
molecular subtype and treatment received. We assessed whether the effect
of HD-PB chemotherapy versus conventional chemotherapy on survival,
expressed as the HR, differed by BRCA1-like
CGH status based on
multivariate proportional hazards regression with an interaction term,
adjusting for potential confounders. All calculations were carried out using
the statistical package SPSS 15.0.1 (for Windows) (SPSS Inc., Chicago, IL,
USA).
results
Of the 320 randomly selected patients, 90 could not be analysed
with aCGH due to unavailability or low quality of tumour
tissue (i.e. tumour percentage, DNA yield, quality of DNA
reﬂected by the aCGH quality score). In Figure 1, reasons for
dropout are listed. Our selection held more ER- and PR-
negative patients than the HER2-negative patients not selected
for these analyses. Otherwise, characteristics and treatments of
these 230 cases did not differ from those HER2-negative cases
of the RCT not in current analyses (Supplemental Table S2,
available at Annals of Oncology online).
Forty-one of the 230 tumours (18%) were scored as BRCA1
like
CGH. Patient characteristics did not differ by treatment arm
within the BRCA1- or non-BRCA1-like
CGH subgroups (Table 1).
When compared with patients with non-BRCA1-like
CGH
tumours, patients with BRCA1-like
CGH tumours were generally
younger and more often treated with breast-conserving surgery;
their tumours were more often poorly differentiated, triple-
negative, basal-like and P53-positive (Table 1).
outcome according to treatment in stage III series
by BRCA1-like
CGH classiﬁcation
The beneﬁcial effect of HD-PB chemotherapy compared with
conventional chemotherapy differed between patients with
BRCA1-like
CGH tumours and those with non-BRCA1-like
CGH
tumours (adjusted test for interaction P = 0.006). Among patients
with BRCA1-like
CGH tumours, the risk of recurrence was eightfold
decreased after HD-PB chemotherapy compared with
conventional chemotherapy (adjusted HR 0.12, 95% CI 0.04–0.43;
Table 2 and Figure 2B), while in patients with non-BRCA1-
like
CGH tumours, no signiﬁcant treatment difference was observed
(adjusted HR 0.78, 95% CI 0.50–1.20; Table 2 and Figure 2A).
Similar results were observed forO S( F i g u r e2 Ca n dD ,a d j u s t e d
test for interaction P = 0.04, data not shown). All analyses were
adjusted for pathological tumour size, number of positive lymph
nodes, Bloom–Richardson grade, triple-negative status and
treatment as these were signiﬁcantly associated with RFS
(supplemental Table S3, available at Annals of Oncology online).
association of the BRCA1-like
CGH classiﬁer within
the triple-negative subgroup with BRCA1 mutation
status, BRCA1 promoter methylation status and
basal-like Nielsen phenotype
In the TN subgroup (n = 60), eight of the 13 BRCA1-mutated
tumours had a BRCA1-like
CGH proﬁle (Table 3). All 12
tumours with methylation of the BRCA1 promoter displayed
Patient Selection stage-III series
Randomly selected HER2-
negative patients (n=320)
aCGH analysis performed
(n=245)
621 HER2-negative 
patients included in original
RCT (RCT total: 885)
Unselected HER2-negative 
patients (n=301)
Did not complete assigned 
treatment (n=9)
Technical difficulties CGH 
no profile available 
(n=24)
aCGH profiles did not pass 
quality check (n=15)
Tissue missing, tumor 
percentage < 60%, not 
enough DNA (n=42)
Per protocol analysis of 
patients with aCGH profiles 
available (n=230)
Figure 1. Flow diagram of patients in the study. Flow of patients through
the study including number of patients in each stage. Reasons for dropout
are listed. aCGH, array comparative genomic hybridisation.
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Variable Patients with non-BRCA1-like
CGH tumours Patients with BRCA1-like
CGH tumours P
b
Conventional chemotherapy HD-PB chemotherapy Total P
a Conventional chemotherapy HD-PB chemotherapy Total P
a
N % N % N % N % N % N %
Total 95 50.3 94 49.7 189 100.0 23 56.1 18 43.9 41 100.0 n.s
Age in categories, years
£40 21 22.1 22 23.4 43 22.8 n.s 11 47.8 9 50.0 20 48.8 n.s 0.002
>40 74 77.9 72 76.6 146 77.2 12 52.2 9 50 21 51.2
Type of surgery
Breast-conserving therapy 16 16.8 18 19.1 34 18.0 n.s 8 34.8 6 33.3 14 34.1 n.s 0.03
Mastectomy 79 83.2 76 80.9 155 82.0 15 65.2 12 66.7 27 65.9
Pathological tumour classiﬁcation
pT1 or pT2 80 84.2 78 83.0 158 83.6 n.s 19 82.6 17 94.4 36 87.8 n.s n.s
pT3 15 15.8 14 14.9 29 15.3 4 17.4 1 5.6 5 12.2
Unknown 0 0.0 2 2.1 2 1.1 0 0.0 0 0.0 0 0.0
Number of positive lymph nodes
4–9 66 69.5 59 62.8 125 66.1 n.s 15 65.2 11 61.1 26 63.4 n.s n.s
‡10 29 30.5 35 37.2 64 33.9 8 34.8 7 38.9 15 36.6
Histological grade
I + II 63 66.3 63 67.0 126 66.7 n.s 4 17.4 1 5.6 5 12.2 n.s <0.001
III 30 31.6 27 28.7 57 30.2 19 82.6 14 77.8 33 80.5
Not determined 2 2.1 4 4.3 6 3.2 0 0.0 3 16.7 3 7.3
Triple-negative status
ER or PR positive (‡10%) 82 86.3 81 86.2 163 86.2 n.s 4 17.4 1 5.6 5 12.2 n.s <0.001
Triple negative 13 13.7 13 13.8 26 13.8 18 78.3 16 88.9 34 82.9
Unknown 0 0.0 0 0.0 0 0.0 1 4.3 1 5.6 2 4.9
Nielsen basal-like breast cancer deﬁnition
Negative 89 93.7 85 90.4 174 92.1 n.s 7 30.4 2 11.1 9 22.0 n.s <0.001
Basal-like 6 6.3 9 9.6 15 7.9 15 65.2 15 83.3 30 73.2
Unknown 0 0.0 0 0.0 0 0.0 1 4.3 1 5.6 2 4.9
P53 status
Negative (<10%) 51 53.7 65 69.1 116 61.4 0.05 8 34.8 7 38.9 15 36.6 n.s 0.02
Positive (‡10%) 40 42.1 26 27.7 66 34.9 12 52.2 8 44.4 20 48.8
Unknown 4 4.2 3 3.2 7 3.7 3 13.0 3 16.7 6 14.6
Patients with unknown values were omitted and P values were calculated using the Fisher’s exact test.
aAssociation within subgroup.
bAssociation between subgroups.
CGH, comparative genomic hybridisation; ER, estrogen receptor; n.s., non-signiﬁcant; PR, progesterone receptor.
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1a BRCA1-like
CGH proﬁle (Table 3). All BRCA1-mutated
tumours had an unmethylated BRCA1 promoter. TN BRCA1-
like
CGH tumours displayed in 88% (30/34), a basal-like
phenotype. Conversely, 33% (15/45) of the basal-like tumours
scored as non-BRCA1-like
CGH (Table 3). To explore the
predictive potential of above markers and to put the BRCA1-
like
CGH classiﬁer in perspective, we assessed whether the effect
of HD-PB chemotherapy on RFS differed by each separate
marker with an interaction term.
outcome according to treatment in the triple-
negative subgroup by different markers
Inﬂuence of the BRCA1-like
CGH classiﬁer on differential
treatment effect in the TN subgroup was similar to that
observed in the total group of 230 patients (P interaction =
0.05). Subsequently, no substantial modiﬁcation was seen of the
HRs for RFS in BRCA1-like
CGH (adjusted HR: 0.17, 95% CI
0.05–0.60; Figure 2F and Table 4) and non-BRCA1-like
CGH
patients (adjusted HR: 0.88, 95% CI 0.30–2.57; Figure 2E and
Table 4). BRCA1 methylation interacted signiﬁcantly with the
effect of HD-PB chemotherapy on RFS in the TN subgroup
(interaction P = 0.02; Table 4). HD-PB chemotherapy effects
differed less strongly by basal-like status or BRCA1 mutation
status and homogeneity was not rejected (P interaction: P =
0.83, P = 0.76, respectively, Table 4).
toxicity of HD-PB chemotherapy and marker status
There was no correlation between BRCA1 status as assessed
by mutation, methylation or aCGH analysis and early or late
(non-)haematological toxicity of HD-PB chemotherapy.
discussion
In this study, we observed that a BRCA1-like
CGH classiﬁer,
derived from BRCA1-mutated tumours, was capable of
selecting HER2-negative patients who had a signiﬁcantly better
outcome after HD-PB chemotherapy compared with
conventional chemotherapy while there was no such evidence
for unselected non-BRCA1-like
CGH patients (signiﬁcant P
interactions, RFS and OS). We found a similar high proportion
Table 2. Multivariate Cox proportional hazard analysis of the risk of
recurrence (recurrence-free survival) in the stage III series
Variable All patients stage III series
Number of
events/number
of patients
Hazard
ratio
95% CI P
Lymph nodes
4–9 61/151 1.00
‡10 43/79 1.71 1.13–2.59 0.01
p T-stage
1 or 2 82/194 1.00
3 22/34 1.95 1.19–3.22 0.009
Histological grade
I + II 55/131 1.00
III 47/90 1.54 0.98–2.40 n.s.
Hormone receptor status
ER and PR negative
(<10%)
32/60 1.00
ER or PR positive (‡10%) 71/168 0.74 0.43–1.25 n.s.
aCGH classiﬁer
Non-BRCA1-like
CGH
tumour
83/189 1.00
BRCA1-like
CGH tumour 21/41 2.07 1.02–4.17 0.04
BRCA1-like
CGH tumour
Conventional
chemotherapy
17/23 1.00
High-dose chemotherapy 4/18 0.12* 0.04–0.43 0.001
Non-BRCA1-like
CGH tumour
Conventional
chemotherapy
47/95 1.00
High-dose chemotherapy 36/94 0.78* 0.50–1.20 n.s.
Homogeneity of both hazard ratios was rejected based on an interaction
term with *P =0.006; Number of events is not equal for all variables since
some patients have missing data; maximum missing variables (i.e. events)
of all patients stage III series is 2/104 events.
aCGH, array comparative genomic hybridisation; CI, conﬁdence interval;
CGH, comparative genomic hybridisation; ER, estrogen receptor; n.s., non-
signiﬁcant; p, pathological; PR, progesterone receptor.
Table 3. Distribution of patients with a BRCA1 mutation, a BRCA1
methylation and basal-like status between BRCA1-like
CGH and non-
BRCA1-like
CGH patients
Variable Patients with
non-BRCA1-like
CGH
tumours
Patients with
BRCA1-like
CGH
tumours
P
N % N %
BRCA1 mutation status
a
No mutation
detected
19 73.1 26 76.5 n.s.
Mutation
present
5
b 19.2 8 23.5
Undetermined 2 7.7 0 0.0
BRCA1-promoter methylation status
a
Unmethylated 25 96.2 20 58.8 0.001
Methylated 0 0.0 12 35.3
Undetermined 1 3.8 2 5.9
Nielsen basal-like breast cancer deﬁnition
a
Negative 11 42.3 4 11.8 0.01
Basal-like 15 57.7 30 88.2
aAnalyses carried out in the triple-negative subset of the stage III series (n =
60). In seven BRCA1-like
CGH tumours, only 62% of the types of BRCA1
mutations prevalent in the Netherlands were determined due to technical
difﬁculties instead of the intended 73%. Similarly, of one non-BRCA1-
like
CGH tumours 40% of the type of BRCA1 mutations could be tested.
bOne patient scored just below the predetermined threshold of 0.63 the
BRCA1-like
CGH classiﬁer (score: 0.61). BRCA1 mutations were not
necessarily germ line mutations since we tested DNA derived from the
tumours. In all undetermined cases, all DNA had been used for array
comparative genomic hybridisation analysis and no additional analyses
could be carried out. Patients with unknown values were omitted and
P values were calculated using the Fisher’s exact test.
CGH, comparative genomic hybridisation; n.s., non-signiﬁcant.
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CGH tumours (34/39,
87%) as in BRCA1-mutated tumours [34, 35] and therefore
examined the classiﬁer’s association with BRCA1 mutation,
BRCA1 methylation and basal-like status in the TN subgroup.
We found that 63% (20/32) BRCA1-like
CGH tumours
harboured either a BRCA1 mutation (n = 8) or BRCA1
methylation (n = 12), and these features were mutually
exclusive. Furthermore, BRCA1-methylation status showed
potential for the identiﬁcation of patients with selective beneﬁt
of HD-PB chemotherapy; however, due to the small numbers,
these data should be interpreted with caution and no
conclusions can be drawn at this stage.
The BRCA1-like
CGH classiﬁer displayed two characteristics
required for efﬁcacy in clinical practice. It selected a substantial
number of patients (41/230). Secondly, in this series, it
predicted a large differential treatment effect; selected patients
showed an improved outcome after HD-PB chemotherapy
when compared with standard anthracycline-based adjuvant
chemotherapy and, just as importantly, unselected patients did
not seem to have any advantage over standard chemotherapy as
demonstrated by their HRs being close to one. Furthermore, it
showed a large overlap with the other markers, 8/13 BRCA1-
mutated tumours scored as BRCA1 like
CGH. Why all BRCA1-
mutated tumours did not score as BRCA1 like
CGH is a matter of
speculation. In two cases, the tumour cell content was
estimated to be below 60% at blinded repeat examination,
which may have caused excess ‘dilution’ of the tumour DNA by
normal DNA. In a third case, a BRCA1-like
CGH score of 0.61
was found, while 0.63 was the predetermined threshold for
a BRCA1-like
CGH status. In tumours with a low tumour
percentage or tumours scoring near the threshold,
conﬁrmation of the test results by BRCA1 sequencing may be
advisable. In addition, many BRCA1-like
CGH tumours had
a basal-like phenotype based on the Nielsen deﬁnition [33] in
our series (75%). However, basal-like phenotype and BRCA1-
like
CGH do not seem to be identical markers since a substantial
amount, one-third (15/45), of the basal-like tumours scored as
non-BRCA1-like
CGH. Of the BRCA1-methylated tumours, 12/
12 scored as BRCA1 like
CGH; given the small numbers, it could
well be that the accuracy of the BRCA1-like
CGH classiﬁer for
identifying BRCA1-methylated cases is overestimated.
However, it should be noted that in our study one-third of the
BRCA1-like
CGH tumours showed BRCA1-promoter
methylation, supporting our hypothesis that the classiﬁer also
identiﬁes patients with BRCA1 loss conferred by causes other
than mutations. This hypothesis was further strengthened by
a recent publication with a similar approach, in which BRCA1/
2-mutated ovarian cancers were used to develop a gene
expression proﬁle of BRCAness [36]. In this study, 20/70
sporadic ovarian cancer patients scored as having BRCAness
and had a signiﬁcantly longer disease-free survival after
platinum agents [36].
Our study is in line with previous ﬁndings in which BRCA1
methylation was associated with good response to a platinum
agent in 28 triple-negative breast cancer (TNBC) patients in the
neoadjuvant setting [37]. In that study using tumour response
according to Miller–Payne criteria as a surrogate end point for
outcome, 2/2 TNBC patients with a BRCA1 mutation achieved
a pathological complete remission (pCR) on conventionally
dosed cisplatin [37]. Similarly, Byrski et al. [9] studied a cohort
of 102 BRCA1 mutation carriers from 16 hospitals who had
received various chemotherapy regimens in the neoadjuvant
setting. Ten of the 12 patients (83%) achieved pCR on cisplatin
monotherapy, while only 11 of the 51 (22%) patients who had
received an anthracycline-based regimen achieved pCR [9].
Byrski et al. [9] cautioned, however, that their study was an
observational study and patients in the cisplatin group had
smaller tumours, were more often node negative and none of
them had received prior chemotherapy, making direct
comparison among treatment groups difﬁcult. We did not
observe a greater beneﬁcial effect of platinum-based HD-PB
chemotherapy over conventional chemotherapy in BRCA1-
mutated compared with non-BRCA1-mutated breast cancers in
the context of a RCT, which might at least partly be caused by
the small numbers. Furthermore, we studied survival data with
a median follow-up time of 7 years as the end point, instead of
response to neoadjuvant chemotherapy. Additionally, it has
been suggested that mutation site in the BRCA1 gene could
inﬂuence sensitivity to these agents [38]. Similarly, secondary
mutations restoring the BRCA1 reading frame in BRCA1-
mutated cancers could lead to resistance, as has been described
for ovarian cancers [39]. The low incidence of BRCA1-mutated
breast cancer will make it challenging to resolve these
remaining questions.
We did not ﬁnd a signiﬁcantly different beneﬁt of HD-PB
chemotherapy over conventional chemotherapy between basal-
IHC and non-basal-IHC patients within the TN subgroup. In
contrast, Diallo-Danebrock et al. [40] found an improved
outcome after high-dose chemotherapy compared with dose-
dense chemotherapy in high-risk breast cancer patients with
a basal-IHC phenotype. However, this was not studied in the
TN subgroup of patients and high-dose chemotherapy used in
this study did not include a platinum salt. It is important to
dissect TNBC in at least two subgroups, as TNBC has been
shown to derive substantial beneﬁt from addition of taxanes
[41, 42], while in preclinical studies, relative resistance against
taxanes has been demonstrated for breast cancer cells lacking
functional BRCA1 [6, 7]. We hypothesise therefore that
BRCA1-like
CGH TNBC patients should receive DSB-inducing
regimens, while non-BRCA1-like
CGH TNBC patients should
Figure 2. Association of BRCA1-like
CGH classiﬁcation with outcome after high-dose platinum-based (HD-PB) chemotherapy and conventional
chemotherapy in all patients of the stage III series and the triple-negative subgroup. Kaplan–Meier survival curves according to the BRCA1 classiﬁcation of
patients who had been randomly assigned between HD chemotherapy and conventional chemotherapy. (A) Recurrence-free survival of non-BRCA1-like
CGH
HER2-negative patients. (B) Recurrence-free survival of BRCA1-like
CGH HER2-negative patients. (C) Overall survival of non-BRCA1-like
CGH HER2-
negative patients. (D) Overall survival of BRCA1-like
CGH HER2-negative patients. (E) Recurrence-free survival of non-BRCA1-like
CGH ‘triple-negative’
patients. (F) Recurrence-free survival of BRCA1-like
CGH triple-negative patients. CGH, comparative genomic hybridisation.
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initiated to test this hypothesis (NCT01057069).
The resolution of the CGH platform used in our study was
lower compared with newer commercially available platforms.
Nevertheless, it is unlikely that ﬁndings based on low resolution
disappear on high resolution. Moreover, as we tested an
existing classiﬁer developed several years ago, we were conﬁned
to using the same platform. A limitation of our study was that it
consisted of an unplanned subgroup analysis in a RCT.
However, the use of a RCT allowed us to determine whether the
association between markers and improved survival was related
to either selective sensitivity to high-dose platinum-based
chemotherapy or to general chemotherapy sensitivity/
resistance.
Despite increased toxicity of HD-PB chemotherapy in the
whole group, we did not observe a difference between patients
with or without a BRCA1-like
CGH, BRCA1-methylated or
BRCA1-mutated tumour. This corroborates with the
synthetic lethality concept in which cells with a functional
BRCA1 protein maintain their homologous recombination
function and are capable of repairing the DSBs induced by the
HD-PB chemotherapy, including normal tissues of BRCA1
mutation carriers that did not lose the wild-type allele. In an era
where we have largely abandoned HD-PB chemotherapy as
a toxic regimen with no survival beneﬁt, it is tempting to
disregard the potential of the predictive markers investigated in
our study, especially given the controversy surrounding this
subject [43–45]. However, RFS differences observed between
HD-PB chemotherapy and conventional, anthracycline-based
chemotherapy in the BRCA1-like
CGH are remarkable.
Presumably, this difference observed is an overestimation of
the actual effect and should be conﬁrmed in other studies.
Because of constraints of the trial, unfortunately, we could not
determine whether the platinum-based DSB-inducing
regimen would have resulted in a similar improved outcome
had it been conventionally dosed. We can only speculate that
given the molecular background of the aCGH classiﬁer (derived
from BRCA1-mutated tumours) the type of agents is
mandatory, all causing DSBs in the DNA, and explains the
beneﬁcial effect of HD-PB chemotherapy. This is particularly
interesting given the fact that, recently a far less toxic, new
DSB-inducing agent has been introduced in the form of
poly(ADP) (PARP)-ribose inhibitors, which has been shown to
target BRCA1-mutated breast cancer[8, 46]. Therefore, it would
be interesting to consider the subgroup identiﬁed by the aCGH
classiﬁer for studies with PARP inhibitors only or in
Table 4. Multivariate Cox proportional hazard analysis of the risk of recurrence (recurrence-free survival) for multiple markers in the triple-negative
subgroup
Variable
a Number of events/
number of patients
Hazard ratio 95% CI P
Nielsen basal-like tumour
Conventional chemotherapy 15/21 1.00
High-dose chemotherapy 8/24 0.36* 0.14–0.94 0.04
Non-basal-like tumour
Conventional chemotherapy 7/10 1.00
High-dose chemotherapy 2/5 0.45* 0.09–2.30 n.s.
BRCA1-like
CGH tumour
Conventional chemotherapy 13/18 1.00
High-dose chemotherapy 4/16 0.17** 0.05–0.60 0.006
Non-BRCA1-like
CGH tumour
Conventional chemotherapy 9/13 1.00
High-dose chemotherapy 6/13 0.88** 0.30–2.57 n.s.
BRCA1-mutated tumour
Conventional chemotherapy 3/6 1.00
High-dose chemotherapy 3/7 0.48*** 0.08–2.98 n.s.
No mutation found in tumour
Conventional chemotherapy 19/25 1.00
High-dose chemotherapy 6/20 0.35*** 0.13–0.91 0.03
BRCA1-methylated tumour
Conventional chemotherapy 6/7 1.00
High-dose chemotherapy 0/5 0.00**** 0–0.17
b <0.001
b
Unmethylated tumour
Conventional chemotherapy 15/23 1.00
High-dose chemotherapy 9/22 0.55**** 0.23–1.31 n.s.
aAll analyses shown were adjusted for marker of interest, lymph node status, pathological T-stage and histological grade as in Table 2. Homogeneity of both
hazard ratios was tested with an interaction term resulting in: *P = 0.83, **P = 0.05, ***P = 0.76, ****P = 0.02.
bThe upper conﬁdence bound is based on a model restricted to patients with methylated tumours because it could not be calculated in the model including
methylated and unmethylated tumour patients. Number of events is not equal for all variables since some patients have missing data; maximum missing
variables (i.e. events) is 2/32.
CGH, comparative genomic hybridisation; CI, conﬁdence interval.
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usefulness of these markers for prediction of PARP inhibitor
beneﬁt, we have initiated a small pilot study in patients
treated with an olaparib-containing regimen in the metastatic
setting.
In conclusion, our data suggest that the BRCA1-like
CGH
classiﬁer might be predictive for selective HD-PB
chemotherapy beneﬁt, a DSB-inducing regimen. However,
what the role of BRCA1 methylation, basal-like and BRCA1-
mutation status is remains unclear due to small numbers. This
is the ﬁrst study in breast cancer patients in which all these
markers were evaluated in the context of a RCT with long-term
outcome. However, these ﬁndings do not justify the
introduction of HD-PB chemotherapy as a standard
treatment option for breast cancer patients with a BRCA1-
like
CGH tumour. The use of the aCGH classiﬁer as
a predictive marker for HD-PB chemotherapy, but especially
for other DSB-inducing regimens (such as other alkylators,
preferably in combination with PARP inhibitors) and the
additive value of additional biomarkers, such as BRCA1
methylation, separately and in combination warrants
further investigation and validation, preferably in prospective
RCTs.
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